Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Yoel Lubell

Professor Yoel Lubell

Podcast interview

The economics of tropical diseases

Economics and health are interlinked in many ways, as seen in the vicious cycle between poverty and ill health. Merging data from various research areas within economic models allows a more efficient use of scarce resources. Economic evaluation helps ensure that cost effective interventions are included in policy recommendations.

View podcast transcript

Social media

Yoel Lubell

Professor of Global Health

Head of EIRG

I lead the Economics and Implementation Research Group (EIRG) at the Mahidol Oxford Tropical Medicine Research Unit in Bangkok, Thailand. EIRG focuses on the evaluation of diagnostics, treatments and vaccines for malaria and other infectious diseases. These evaluations are pursued using a variety of approaches ranging from economic and epidemiological modelling through laboratory investigations to clinical trials and qualitative research. Our ultimate aim is to provide policy makers with pragmatic and context specific assessments of the impact of new interventions if implemented in routine care. Where relevant we strive to take a broader view of the costs and benefits of new interventions accounting for factors such as their indirect impact on disease transmission and antimicrobial resistance, and how the interventions’ cost-effectiveness varies in different epidemiological and socio-economic settings, and in response to contextual factors such as health seeking behaviour and health workers' compliance with diagnostic test results and treatment guidelines.

An educational video for patients on the distinction between viral and bacterial infections, and why it is important to target antibiotics appropriately.
Data from the largest study to date comparing CRP and procalcitonin as biomarkers for bacterial infection in tropical settings, indicating that CRP outperforms procalcitonin for these purposes
The study team for a randomised controlled trial on CRP guided treatment in febrile illness at a site-opening visit